IL110855A - Methods for inducing antigen-specific t cell tolerance - Google Patents

Methods for inducing antigen-specific t cell tolerance

Info

Publication number: IL110855A
Authority: IL; Israel
Prior art keywords: cell; methods; antigen; receptor; tolerance
Prior art date: 1993-09-02

Application number

IL11085594A

Other languages

English (en)

Other versions

IL110855A0 (en

Original Assignee

Dartmouth College

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-02

Filing date

1994-09-02

Publication date

1999-04-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26814047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL110855(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-04-25 Priority claimed from US08/232,929 external-priority patent/US5869049A/en

1994-09-02 Application filed by Dartmouth College filed Critical Dartmouth College

1994-11-28 Publication of IL110855A0 publication Critical patent/IL110855A0/xx

1999-04-11 Publication of IL110855A publication Critical patent/IL110855A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Urology & Nephrology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Cell Biology (AREA)
Hematology (AREA)
Food Science & Technology (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Toxicology (AREA)
Zoology (AREA)
Microbiology (AREA)
Transplantation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

IL11085594A 1993-09-02 1994-09-02 Methods for inducing antigen-specific t cell tolerance IL110855A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11625593A	1993-09-02	1993-09-02
US08/232,929 US5869049A (en)	1993-09-02	1994-04-25	Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists

Publications (2)

Publication Number	Publication Date
IL110855A0 IL110855A0 (en)	1994-11-28
IL110855A true IL110855A (en)	1999-04-11

Family

ID=26814047

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL11085594A IL110855A (en)	1993-09-02	1994-09-02	Methods for inducing antigen-specific t cell tolerance

Country Status (17)

Country	Link
US (5)	US5747037A (xx)
EP (2)	EP0721346B1 (xx)
JP (3)	JP3007977B2 (xx)
CN (2)	CN100341896C (xx)
AT (2)	ATE188487T1 (xx)
AU (2)	AU696235B2 (xx)
DE (2)	DE69422523T2 (xx)
DK (2)	DK0721469T3 (xx)
ES (2)	ES2120067T3 (xx)
FI (2)	FI105528B (xx)
GR (2)	GR3027658T3 (xx)
HU (2)	HU220296B (xx)
IL (1)	IL110855A (xx)
NO (2)	NO321098B1 (xx)
NZ (3)	NZ549136A (xx)
PT (1)	PT721469E (xx)
WO (2)	WO1995006666A1 (xx)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5962406A (en) *	1991-10-25	1999-10-05	Immunex Corporation	Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US7070777B1 (en)	1991-11-15	2006-07-04	The Trustees Of Columbia University In The City Of New York	Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) *	1991-11-15	1995-12-12	The Trustees Of Columbia University In The City Of New York	Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
EP0721346B1 (en) *	1993-09-02	1998-06-10	Trustees of Dartmouth College	Methods for inducing antigen-specific t cell tolerance
US5683693A (en)	1994-04-25	1997-11-04	Trustees Of Dartmouth College	Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) *	1995-01-26	1999-03-02	Bristol-Myers Squibb Company	Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
JPH08239324A (ja) *	1995-03-03	1996-09-17	Fusanori Hamashima	免疫抑制剤
US5833987A (en) *	1995-06-07	1998-11-10	Trustees Of Dartmouth College	Treatment of T cell mediated autoimmune disorders
US6113898A (en)	1995-06-07	2000-09-05	Idec Pharmaceuticals Corporation	Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7175847B1 (en)	1995-06-07	2007-02-13	Biogen Idec Inc.	Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US7153508B2 (en)	1995-06-07	2006-12-26	Biogen Idec Inc.	Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US6440418B1 (en) *	1995-11-07	2002-08-27	Idec Pharmaceuticals Corporation	Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) *	1995-11-07	1999-12-14	Idec Pharmaceuticals Corporation	Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en)	1995-12-01	2002-01-22	The Trustees Of Columbia University In The City Of New York	Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
JP4751493B2 (ja) *	1996-03-20	2011-08-17	ブリストル−マイヤーズスクイッブカンパニー	Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物
DE19634159C1 (de) *	1996-08-23	1997-09-25	Gsf Forschungszentrum Umwelt	Induktion einer Tumorimmunität durch Injektion von Hybridzellen
AU4352997A (en) *	1996-08-30	1998-03-19	Genzyme Corporation	Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies
EP0966302B1 (en) *	1997-01-10	2007-03-14	Biogen Idec MA Inc.	Methods of therapeutic administration of anti-cd40l compounds
US6428782B1 (en) *	1997-05-23	2002-08-06	Hadasit Medical Research Services And Development Ltd.	Non-myeloablative tolerogenic treatment
ES2277460T3 (es)	1998-12-14	2007-07-01	Genetics Institute, Llc	Cadena del receptor de la citoquina.
US7553487B2 (en) *	1998-12-14	2009-06-30	Genetics Institute, Llc	Method and compositions for treating asthma
AU2845400A (en) *	1998-12-24	2000-07-31	Phairson Medical Inc.	Treatment and prevention of immune rejection reactions
WO2000072882A1 (fr) *	1999-06-01	2000-12-07	Eisai Co., Ltd.	Agents prophylactiques du purpura thrombocytopenique idiopathique
AU5641100A (en) *	1999-06-29	2001-01-31	University Of Massachusetts	Methods for inducing t cell non-responsiveness to a tissue or organ graft
US20020028178A1 (en) *	2000-07-12	2002-03-07	Nabil Hanna	Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
EP1262194A4 (en) *	2000-03-06	2003-05-07	Eisai Co Ltd	HEALING AND PREVENTIVE AGENTS FOR THE ANTIPHOSPHOLIPID-ANTIBODY SYNDROME
AU2001251612A1 (en)	2000-04-14	2001-10-30	Millennium Pharmaceuticals, Inc.	Roles of jak/stat family members in tolerance induction
MXPA02010507A (es) *	2000-04-25	2003-05-14	Idec Pharma Corp	Administracion intratecal de rituximab para el tratamiento de linfomas del sistema nervioso central.
JP2003533488A (ja)	2000-05-12	2003-11-11	ベス・イスラエル・ディーコニス・メディカル・センター・インコーポレーテッド	免疫抑制を達成するための組成物および方法
EP1299542A2 (en) *	2000-06-06	2003-04-09	Idec Pharmaceuticals Corporation	Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
US20040022787A1 (en)	2000-07-03	2004-02-05	Robert Cohen	Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CA2413190C (en)	2000-07-03	2009-04-07	Bristol-Myers Squibb Company	Methods for treating rheumatic diseases using a soluble ctla4 molecule
WO2002040050A1 (en) *	2000-11-14	2002-05-23	The University Of Louisville Research Foundation, Inc.	Non-lethal methods for conditioning a recipient for bone marrow transplantation
US7829084B2 (en) *	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
US20030133939A1 (en) *	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) *	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US20030211107A1 (en) *	2002-01-31	2003-11-13	Kandasamy Hariharan	Use of CD23 antagonists for the treatment of neoplastic disorders
US20020159996A1 (en) *	2001-01-31	2002-10-31	Kandasamy Hariharan	Use of CD23 antagonists for the treatment of neoplastic disorders
US20070065436A1 (en) *	2001-01-31	2007-03-22	Biogen Idec Inc.	Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030103971A1 (en) *	2001-11-09	2003-06-05	Kandasamy Hariharan	Immunoregulatory antibodies and uses thereof
US20040058445A1 (en) *	2001-04-26	2004-03-25	Ledbetter Jeffrey Alan	Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
ATE390931T1 (de)	2001-05-23	2008-04-15	Bristol Myers Squibb Co	Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
EP2075256A2 (en)	2002-01-14	2009-07-01	William Herman	Multispecific binding molecules
US20030180292A1 (en) *	2002-03-14	2003-09-25	Idec Pharmaceuticals	Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20030219436A1 (en) *	2002-03-15	2003-11-27	Ledbetter Jeffrey A.	Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
WO2003086463A1 (en) *	2002-04-03	2003-10-23	Keio University	Remedies for pemphigus containing cd40l antagonist as the active ingredient
DK1517921T3 (da) *	2002-06-28	2006-10-09	Domantis Ltd	Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
CN1326878C (zh) *	2003-04-29	2007-07-18	中国抗体制药有限公司	抗人非何杰金淋巴瘤嵌合抗体及其衍生物与应用
AU2011224032B2 (en) *	2003-06-13	2013-01-31	Biogen Ma Inc.	Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
JP4667383B2 (ja) *	2003-06-13	2011-04-13	バイオジェン・アイデック・エムエイ・インコーポレイテッド	アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用
US7754209B2 (en)	2003-07-26	2010-07-13	Trubion Pharmaceuticals	Binding constructs and methods for use thereof
PL1711528T3 (pl)	2003-12-23	2012-11-30	Genentech Inc	Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13
US7501121B2 (en) *	2004-06-17	2009-03-10	Wyeth	IL-13 binding agents
US20090098142A1 (en) *	2004-06-09	2009-04-16	Kasaian Marion T	Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) *	2004-06-09	2006-07-26	Wyeth Corp	Anticuerpos contra la interleuquina-13 humana y usos de los mismos
EA014226B1 (ru)	2004-07-26	2010-10-29	Байоджен Айдек Ма Инк.	Антитела к cd154, их фрагменты и способы применения антител и фрагментов
US7563443B2 (en)	2004-09-17	2009-07-21	Domantis Limited	Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006081620A1 (en) *	2005-02-02	2006-08-10	Newsouth Innovations Pty Limited	Cd4+ cd25+ t-cells activated to a specific antigen
CN100423775C (zh) *	2005-04-15	2008-10-08	中国农业科学院兰州兽医研究所	牛衣原体病灭活疫苗及其制备与检验方法
JP5421590B2 (ja)	2005-05-18	2014-02-19	ノバルティスアーゲー	自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法
HUE026303T2 (hu) *	2005-07-25	2016-06-28	Emergent Product Dev Seattle	B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
WO2007109321A2 (en) *	2006-03-20	2007-09-27	The Regents Of The University Of California	Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
CN105837690A (zh) *	2006-06-12	2016-08-10	新兴产品开发西雅图有限公司	具有效应功能的单链多价结合蛋白
EP2052076A4 (en)	2006-08-02	2010-07-14	Newsouth Innovations Pty Ltd	METHOD FOR IDENTIFYING ANY ANTIGEN-ACTIVATED, CD8-EXPRESSING CD4 + CD25 + T-CELLS
RU2009140134A (ru) *	2007-04-23	2011-05-27	Вайет (Us)	Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений
CA2698343C (en)	2007-09-04	2018-06-12	The Regents Of The University Of California	High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
EP2052848A1 (de)	2007-10-27	2009-04-29	Joint Solar Silicon GmbH & Co. KG	Aufbereitung von Formlingen aus Reinstsilizium
AU2009234277B2 (en)	2008-04-11	2014-12-04	Aptevo Research And Development Llc	CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US20100069616A1 (en) *	2008-08-06	2010-03-18	The Regents Of The University Of California	Engineered antibody-nanoparticle conjugates
US8911739B2 (en)	2009-02-10	2014-12-16	Trustees Of Columbia University In The City Of New York	Methods of preventing rejection of transplanted tissue by administering anti-CD40L antibody and dendritic cells loaded with Hsp60sp peptide
CN105837691B (zh) *	2009-03-10	2021-06-29	贝勒研究院	靶向抗原呈递细胞的癌症疫苗
WO2013013708A1 (en)	2011-07-26	2013-01-31	Fundació Institut D'investigació Biomèdica De Bellvitge	Treatment of acute rejection in renal transplant
CN105722532A (zh)	2013-09-13	2016-06-29	豪夫迈·罗氏有限公司	包含纯化的重组多肽的方法和组合物
BR112016004437A2 (pt)	2013-09-13	2017-10-17	Genentech Inc	métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
MA41459A (fr)	2015-02-03	2017-12-12	Als Therapy Development Inst	Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
TN2018000021A1 (en)	2015-07-14	2019-07-08	Immunext Inc	ANTl-CD154 ANTIBODY HAVING IMPROVED BINDING, FUNCTIONAL AND SAFETY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPY.
CA2994825A1 (en)	2015-08-05	2017-02-09	Janssen Biotech, Inc.	Anti-cd154 antibodies and methods of using them
WO2017053469A2 (en)	2015-09-21	2017-03-30	Aptevo Research And Development Llc	Cd3 binding polypeptides
CA2946465C (en)	2015-11-12	2022-03-29	Delta Faucet Company	Ozone generator for a faucet
WO2017201476A1 (en)	2016-05-20	2017-11-23	Regeneron Pharmaceuticals, Inc.	Methods for breaking immunological tolerance using multiple guide rnas
EP3630843A2 (en)	2017-05-24	2020-04-08	ALS Therapy Development Institute	Therapeutic anti-cd40 ligand antibodies
KR102142499B1 (ko) *	2019-09-11	2020-08-10	재단법인 오송첨단의료산업진흥재단	Ykl-40 표적 인간 단일클론항체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5645820A (en) *	1987-06-24	1997-07-08	Autoimmune, Inc.	Treatment of autoimmune diseases by aerosol administration of autoantigens
US5690933A (en) *	1989-05-31	1997-11-25	Glaxo Wellcome Inc.	Monoclonal antibodies for inducing tolerance
US5962406A (en) *	1991-10-25	1999-10-05	Immunex Corporation	Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
CA2121798C (en) *	1991-10-25	2007-07-24	Richard J. Armitage	Novel cytokine
US5474771A (en) *	1991-11-15	1995-12-12	The Trustees Of Columbia University In The City Of New York	Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (en) *	1992-02-14	2010-04-13	Alejandro A. Aruffo	Cd40cr receptor and ligands therefor
WO1994004570A1 (en) *	1992-08-21	1994-03-03	Schering Corporation	Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) *	1992-09-04	1996-07-30	Bristol-Myers Squibb Company	Soluble and its use in B cell stimulation
US5597563A (en) *	1992-09-04	1997-01-28	Beschorner; William E.	Method induction of antigen-specific immune tolerance
EP0721346B1 (en) *	1993-09-02	1998-06-10	Trustees of Dartmouth College	Methods for inducing antigen-specific t cell tolerance
KR100398819B1 (ko) *	1993-09-02	2004-02-05	트러스티스 오브 다트마우스 칼리지	gp39길항제를포함하는약제조성물
US5683693A (en) *	1994-04-25	1997-11-04	Trustees Of Dartmouth College	Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40

1994
- 1994-09-02 EP EP94926677A patent/EP0721346B1/en not_active Revoked
- 1994-09-02 DK DK94926659T patent/DK0721469T3/da active
- 1994-09-02 DE DE69422523T patent/DE69422523T2/de not_active Expired - Fee Related
- 1994-09-02 AT AT94926659T patent/ATE188487T1/de not_active IP Right Cessation
- 1994-09-02 NZ NZ549136A patent/NZ549136A/en not_active IP Right Cessation
- 1994-09-02 EP EP94926659A patent/EP0721469B1/en not_active Expired - Lifetime
- 1994-09-02 ES ES94926677T patent/ES2120067T3/es not_active Expired - Lifetime
- 1994-09-02 NZ NZ273207A patent/NZ273207A/en not_active IP Right Cessation
- 1994-09-02 AT AT94926677T patent/ATE167062T1/de not_active IP Right Cessation
- 1994-09-02 PT PT94926659T patent/PT721469E/pt unknown
- 1994-09-02 JP JP7508291A patent/JP3007977B2/ja not_active Expired - Fee Related
- 1994-09-02 JP JP7508265A patent/JP2991499B2/ja not_active Expired - Fee Related
- 1994-09-02 CN CNB941939189A patent/CN100341896C/zh not_active Expired - Fee Related
- 1994-09-02 CN CN94194007A patent/CN1127351C/zh not_active Expired - Fee Related
- 1994-09-02 HU HU9600521A patent/HU220296B/hu not_active IP Right Cessation
- 1994-09-02 IL IL11085594A patent/IL110855A/xx not_active IP Right Cessation
- 1994-09-02 WO PCT/US1994/009871 patent/WO1995006666A1/en not_active Ceased
- 1994-09-02 AU AU76429/94A patent/AU696235B2/en not_active Ceased
- 1994-09-02 DE DE69411025T patent/DE69411025T2/de not_active Expired - Fee Related
- 1994-09-02 ES ES94926659T patent/ES2143553T3/es not_active Expired - Lifetime
- 1994-09-02 HU HU9700522A patent/HU218610B/hu not_active IP Right Cessation
- 1994-09-02 DK DK94926677T patent/DK0721346T3/da active
- 1994-09-02 WO PCT/US1994/009953 patent/WO1995006481A1/en not_active Ceased
- 1994-09-02 NZ NZ273221A patent/NZ273221A/en not_active IP Right Cessation
1995
- 1995-06-07 US US08/475,847 patent/US5747037A/en not_active Expired - Lifetime
1996
- 1996-03-01 FI FI960980A patent/FI105528B/fi active
- 1996-03-01 FI FI960978A patent/FI106306B/fi active
- 1996-03-01 NO NO19960861A patent/NO321098B1/no not_active IP Right Cessation
- 1996-03-01 NO NO19960862A patent/NO321036B1/no not_active IP Right Cessation
1997
- 1997-08-21 AU AU35183/97A patent/AU707110B2/en not_active Ceased
1998
- 1998-03-27 US US09/049,043 patent/US5876718A/en not_active Expired - Lifetime
- 1998-04-30 US US09/069,871 patent/US6312692B1/en not_active Expired - Lifetime
- 1998-08-14 GR GR980401834T patent/GR3027658T3/el unknown
- 1998-10-01 US US09/164,568 patent/US7722874B2/en not_active Expired - Fee Related
- 1998-10-12 JP JP10289353A patent/JP3098739B2/ja not_active Expired - Fee Related
2000
- 2000-03-29 GR GR20000400784T patent/GR3033095T3/el not_active IP Right Cessation
2006
- 2006-04-17 US US11/405,876 patent/US20060222649A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HU220296B (hu)	2001-11-28
US20020187135A1 (en)	2002-12-12
NO960862D0 (no)	1996-03-01
DK0721469T3 (da)	2000-05-01
AU7642994A (en)	1995-03-22
EP0721469B1 (en)	2000-01-05
IL110855A0 (en)	1994-11-28
US6312692B1 (en)	2001-11-06
DK0721346T3 (da)	1999-03-22
AU696235B2 (en)	1998-09-03
JP3007977B2 (ja)	2000-02-14
FI960978L (fi)	1996-04-29
JP3098739B2 (ja)	2000-10-16
WO1995006666A1 (en)	1995-03-09
JPH09502096A (ja)	1997-03-04
ES2120067T3 (es)	1998-10-16
EP0721346A1 (en)	1996-07-17
CN100341896C (zh)	2007-10-10
DE69422523D1 (de)	2000-02-10
ES2143553T3 (es)	2000-05-16
AU707110B2 (en)	1999-07-01
NZ273207A (en)	1997-09-22
FI960978A0 (fi)	1996-03-01
HUT74246A (en)	1996-11-28
CN1149299A (zh)	1997-05-07
NZ273221A (en)	2001-09-28
DE69411025D1 (de)	1998-07-16
JPH11189543A (ja)	1999-07-13
NO321098B1 (no)	2006-03-20
NO960862L (no)	1996-04-30
AU7644594A (en)	1995-03-22
EP0721469A1 (en)	1996-07-17
CN1134113A (zh)	1996-10-23
NO960861L (no)	1996-04-30
US20060222649A1 (en)	2006-10-05
HUT74250A (en)	1996-11-28
NO321036B1 (no)	2006-03-06
AU678532B2 (en)	1997-05-29
US5876718A (en)	1999-03-02
WO1995006481A1 (en)	1995-03-09
HU218610B (hu)	2000-10-28
DE69411025T2 (de)	1999-01-07
GR3033095T3 (en)	2000-08-31
HU9600522D0 (en)	1996-04-29
FI960980A0 (fi)	1996-03-01
FI105528B (fi)	2000-09-15
ATE188487T1 (de)	2000-01-15
AU3518397A (en)	1997-10-30
PT721469E (pt)	2000-04-28
US7722874B2 (en)	2010-05-25
JP2991499B2 (ja)	1999-12-20
DE69422523T2 (de)	2000-10-12
US5747037A (en)	1998-05-05
EP0721346B1 (en)	1998-06-10
GR3027658T3 (en)	1998-11-30
CN1127351C (zh)	2003-11-12
NZ549136A (en)	2008-02-29
JPH09502186A (ja)	1997-03-04
HU9600521D0 (en)	1996-04-29
FI106306B (fi)	2001-01-15
NO960861D0 (no)	1996-03-01
FI960980A7 (fi)	1996-04-30
ATE167062T1 (de)	1998-06-15

Publication	Publication Date	Title
HU9600522D0 (en)	1996-04-29	Methods for inducing antigen-specific t cell tolerance
Londei et al.	1989	Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis.
Zinkernagel et al.	1997	Antiviral immunity
Rosa et al.	2002	Bone marrow CD8 T cells are in a different activation state than those in lymphoid periphery
EP1530973A3 (en)	2006-12-27	Methods for inducing T cell tolerance to a tissue or organ graft
ATE415173T1 (de)	2008-12-15	Pan dr-bindeproteinen zur erhöhung der immunantwort
BG103948A (en)	2000-07-31	The use of cd40:cd154 binding interrupter to prevent counteradaptive immune responses, particularlynt counteradaptive immune responses, particularly graft rejection graft rejection
AU2003214076A1 (en)	2003-09-09	Method for isolating ligands eg T cell epitopes
AU3925295A (en)	1996-05-23	Novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
Obst et al.	1998	Allo‐and self‐restricted cytotoxic T lymphocytes against a peptide library: evidence for a functionally diverse allorestricted T cell repertoire
Viale et al.	1992	TCR gamma/delta positive lymphocytes after allogeneic bone marrow transplantation
Mariotti et al.	1991	The autoimmune infiltrate of Basedow's disease: analysis at clonal level and comparison with Hashimoto's thyroiditis
EP3177711B1 (en)	2024-04-24	Use of ligands for the programmed cell death receptor conjugated to solid supports for the expansion of human regulatory t cells
Krummel et al.	2000	Thirty–six views of T–cell recognition
Luciani et al.	1986	Self-sparing of long-term in vitro-cloned or uncloned cytotoxic T lymphocytes.
WO1999017787A3 (en)	1999-06-17	Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response
López-Moratalla et al.	1996	Inducible nitric oxide synthase in monocytes from patients with Graves’ disease
van Essen et al.	2000	Role of B cells in maintaining helper T–cell memory
PL1649287T3 (pl)	2009-04-30	Ocena szczepionek zawierających adjuwanty
Fisfalen et al.	1997	Evaluating the role of Th0 and Th1 clones in autoimmune thyroid disease by use of Hu-SCID chimeras
Williams et al.	1986	The role of cellular proliferation in the induction of experimental autoimmune thyroiditis (EAT) in mice
Lomo et al.	1998	Flexibility of the Thyroiditogenic T Cell Repertoire for Murine Autoimmune Thyroiditis in CD8-Deficient (B2m-/-) and T Cell Receptor VBC Congenic Mice
Bass	1989	Two types of T helper cells in mice: Differences in cellular immune functions and cytokine secretion--selective reduction of one type after total lymphoid irradiation
WO2001002005A3 (en)	2001-07-05	Treatment of dentritic cells for induction of immune tolerance

Legal Events

Date	Code	Title
1999-08-17	FF	Patent granted
2000-06-29	KB	Patent renewed
2001-01-11	KB	Patent renewed
2004-11-10	KB	Patent renewed
2008-12-29	KB	Patent renewed
2013-04-30	MM9K	Patent not in force due to non-payment of renewal fees